Skip to main content
. 2024 Jun 24;30(7):2004–2009. doi: 10.1038/s41591-024-03063-x

Fig. 3. Kaplan–Meier analysis of the percentage of patients remaining in the trial in the enrichment phase of BEDROC stratified by dose group.

Fig. 3

The number of patients at risk at days 8, 22, 36, 50, 64, 78 and 92 is presented in the table below the figure. The difference in the restricted mean survival time for the 180 mg treatment group was statistically significantly greater compared with the placebo group (19.0 (95% CI 4.9 to 33.1)).